(Q37196543)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

Molecular target therapies in endometrial cancer: from the basic research to the clinic (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Roberta Tana

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Stefania Cosio

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Antonio Fanucchi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Andrea Riccardo Genazzani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

1 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

Gynecological Endocrinology

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

239-249

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

Current issues in the management of endometrial cancer.

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Molecular pathology of endometrial hyperplasia and carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Lymph node sampling and survival in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Role of complete lymphadenectomy in endometrioid uterine cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Role of minimally invasive surgery in gynecologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Total laparoscopic versus open surgery for stage 1 endometrial cancer: the LACE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

The management of serous papillary uterine cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Chemotherapy for high-risk early-stage endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Current treatment options for endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Hormone therapy in advanced and recurrent endometrial cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Systemic therapy in metastatic or recurrent endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

The role of routine follow-up after gynecological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

The role of the EGFR signaling in tumor microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Identification of a novel mechanism of NF-kappaB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Gene regulation profiles by progesterone and dexamethasone in human endometrial cancer Ishikawa H cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Lapatinib-associated toxicity and practical management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Imatinib: the first 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Expression of imatinib mesylate-targeted kinases in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

eIF-4E expression and its role in malignancies and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Mammalian target of rapamycin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Mammalian target of rapamycin: a new molecular target for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Molecular approaches to resolve diagnostic dilemmas: the case of gastrointestinal stromal tumor and leiomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Emerging drugs for the treatment of metastatic renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and G

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590801953556

10.1080/09513590801953556

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18569027%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference